STUDY OF THE GUT MICROBIOTA COMPOSITION ROLE IN THE CONTEXT OF CHRONIC HEART FAILURE DEVELOPMENT: REVIEW OF CURRENT DATA
Background. Chronic heart failure (CHF) is a global health issue with high mortality rates. According to statistical data, in Kazakhstan, 4.7% of the population suffers from CHF, which amounts to approximately 320,000 people. In the United States, 6.7 million individuals are affected, with projections rising to 8.5 million by 2030. Despite advancements in treatment, mortality rates remain high. Recent studies highlight the role of gut microbiota in systemic inflammation, a key factor in cardiovascular diseases. Exploring the gut microbiota offers a novel perspective for understanding CHF pathogenesis and potential therapeutic interventions.
Aim. The review aims to explore the role of gut microbiota in the development and progression of CHF and examine new methods to improve the clinical status of patients through gut microbiota modulation.
Search strategy. A literature review was conducted using PubMed, Medline, Cochrane Central register of Controlled Trials database, Web of Science, Scopus, https://elibrary.ru, and Google Scholar over the past 10 years, providing information on the role of the gut microbiota in the development and progression of CHF. The review includes works published in Russian and English
Results. Disruption of the intestinal barrier allows endotoxins and microbial metabolites to enter systemic circulation, triggering systemic inflammation and endothelial dysfunction, exacerbating CHF. Gut hypoperfusion and increased permeability further contribute to the disease's progression. Microbial metabolites, such as trimethylamine-N-oxide (TMAO) and short-chain fatty acids (SCFAs), influence systemic inflammation. Elevated TMAO levels are linked to cardiovascular events, while SCFAs have protective effects but are reduced in CHF patients. Gut dysbiosis is prevalent in CHF, marked by altered microbiota composition, including decreased beneficial bacteria and increased pathogenic species. These changes correlate with systemic inflammation and disease severity.
Conclusions. The gut microbiota significantly impacts CHF pathogenesis through its influence on systemic inflammation and metabolic pathways. Modulating gut microbiota presents promising therapeutic opportunities, including dietary adjustments, probiotics, prebiotics, and fecal microbiota transplantation. Further research is essential to optimize interventions and explore the gut-heart axis's role in CHF progression and comorbidities.
Number of Views: 3463
Category of articles:
Reviews
Bibliography link
Bekbosynova M.S., Jetybaeva S.K., Aipov B.R., Nurlan K.R., Sailybaeva A.I., Taukelova A.T., Laiskanov I.A., Aldanysh Zh.Zh., Kushugulova A.R. Study of the Gut Microbiota Composition Role in the Context of Chronic Heart Failure Development: Review of Current Data // Nauka i Zdravookhranenie [Science & Healthcare]. 2024. Vol.26 (6), pp. 122-131. doi 10.34689/SH.2024.26.6.015Related publications:
INTERNATIONAL EXPERIENCE OF PALLIATIVE CARE FOR CANCER PATIENTS: CHALLENGES, ISSUES, AND DEVELOPMENT PROSPECTS. LITERATURE REVIEW
METABOLIC SYNDROME AND ITS ASSOCIATION WITH OVARIAN DYSFUNCTION. LITERATURE REVIEW
PATHOLOGICAL CHANGES IN LUNG TISSUE UNDER THE INFLUENCE OF ELECTRONIC CIGARETTES. LITERATURE REVIEW.
RESPIRATORY SUPPORT FOR CHRONIC HYPERCAPNIC RESPIRATORY FAILURE IN THE OUTPATIENT SETTINGS. LITERATURE REVIEW.
ATRIOVENTRICULAR SEPTAL DEFECT: ETIOLOGY, PATHOGENESIS, CLASSIFICATION, MODERN DIAGNOSTIC METHODS, AND SURGICAL CORRECTION. LITERATURE REVIEW